Literature DB >> 33754203

Reno-protective effects of Phosphodiesterase 5 inhibitors.

Enis Rauf Coskuner1, Burak Ozkan2.   

Abstract

The kidneys are vital organs that play an important role in removing waste materials from the blood, electrolyte balance, blood pressure regulation, and red blood cell genesis. Kidney disease can be caused by various factors, including diabetes, ischemia/reperfusion injury, and nephrotoxic agents. Inflammation and oxidative stress play a key role in the progression and pathogenesis of kidney diseases. Acute kidney injury (AKI) and chronic kidney disease (CKD) are important health problems worldwide, as they are associated with a long-term hospital stay, and increased morbidity and mortality in high-risk patients. Current standard therapeutic options are not sufficient to delay or stop the loss of kidney function. Therefore, it is necessary to develop new therapeutic options. Phosphodiesterase 5 inhibitors (PDE5Is) are a currently available class of drugs that are used to treat erectile dysfunction and pulmonary hypertension in humans. However, recent evidence suggests that PDE5Is have beneficial renoprotective effects via a variety of mechanisms. In this review, the benefits of PDE5 inhibitors in clinical conditions associated with kidney disease, such as diabetic nephropathy, ischemia-reperfusion injury, and acute and chronic kidney injury, are summarized.

Entities:  

Keywords:  Chronic kidney disease; Diabetic nephropathy; Ischemia–reperfusion injury; Kidney protection; Phosphodiesterase inhibitors

Year:  2021        PMID: 33754203     DOI: 10.1007/s10157-021-02051-6

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  72 in total

1.  KDIGO clinical practice guidelines for acute kidney injury.

Authors:  Arif Khwaja
Journal:  Nephron Clin Pract       Date:  2012-08-07

Review 2.  Cardiovascular effects of phosphodiesterase 5 inhibitors.

Authors:  Thorsten Reffelmann; Robert A Kloner
Journal:  Curr Pharm Des       Date:  2006       Impact factor: 3.116

Review 3.  Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use.

Authors:  Andrew T Bender; Joseph A Beavo
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

4.  Erectile dysfunction and the effects of sildenafil treatment in patients on haemodialysis and continuous ambulatory peritoneal dialysis.

Authors:  S Türk; G Karalezli; H Z Tonbul; M Yildiz; L Altintepe; A Yildiz; M Yeksan
Journal:  Nephrol Dial Transplant       Date:  2001-09       Impact factor: 5.992

5.  Chronic renal failure and sexual functioning: clinical status versus objectively assessed sexual response.

Authors:  A W Toorians; E Janssen; E Laan; L J Gooren; E J Giltay; P L Oe; A J Donker; W Everaerd
Journal:  Nephrol Dial Transplant       Date:  1997-12       Impact factor: 5.992

Review 6.  Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy.

Authors:  Judit Gordon; Jeffrey B Kopp
Journal:  Adv Chronic Kidney Dis       Date:  2011-07       Impact factor: 3.620

Review 7.  Cardioprotection with phosphodiesterase-5 inhibition--a novel preconditioning strategy.

Authors:  Rakesh C Kukreja; Ramzi Ockaili; Fadi Salloum; Chang Yin; John Hawkins; Anindita Das; Lei Xi
Journal:  J Mol Cell Cardiol       Date:  2004-02       Impact factor: 5.000

Review 8.  Phosphodiesterase 5 inhibitors: are they cardioprotective?

Authors:  Thorsten Reffelmann; Robert A Kloner
Journal:  Cardiovasc Res       Date:  2009-05-27       Impact factor: 10.787

Review 9.  Phosphodiesterase type 5 inhibitors and kidney disease.

Authors:  Baris Afsar; Alberto Ortiz; Adrian Covic; Abduzhappar Gaipov; Tarik Esen; David Goldsmith; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2015-08-05       Impact factor: 2.370

Review 10.  Emerging drugs for chronic kidney disease.

Authors:  Sergio Stefoni; Giuseppe Cianciolo; Olga Baraldi; Mario Iorio; Maria Laura Angelini
Journal:  Expert Opin Emerg Drugs       Date:  2014-05-16       Impact factor: 4.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.